Dr Molloy joined St George's, University of London in 2012 as a post doctoral researcher, project manager and epidemiologist for the ACTA trial. She was promoted to Lecturer in Epidemiology in 2018 and to Senior Lecturer in 2022 and has since been a co-investigator on the Ambition trial and on the DREAMM and TRIP projects based in sites in South Africa (SA), Botswana, Zimbabwe, Tanzania, Malawi, Uganda and Cameroon. She is currently co-Chief Investigator of the EFFECT Trial which aims to improve treatment regimens to prevent the development of cryptococcal meningitis in Advanced HIV patients in SA and Tanzania. She is also involved in a package of work led by DNDi aiming to develop a sustained-release formulation of flucytosine to simplify inpatient and outpatient treatment of cryptococcal infections (Phase II trials: co-CI for 5FC-PROTECT and co-I for 5FC HIV Crypto)
Dr Molloy completed her MSc in Medical Statistics with distinction at the London School of Hygiene & Tropical Medicine, UK in 2018 and she previously worked as an Epidemiologist for the MalariaGEN consortium in Oxford University. She obtained her PhD in Parasitology at Trinity College Dublin in 2009, working on the epidemiology of Cryptosporidium species in a cohort of children in Nigeria.
She is a Springboard Fellow with the Academy of Medical Sciences (AMS) and an Associate Fellow at the Higher Education Academy, UK. She is a mentor on the both the AMS and SGUL mentorship programs.
CURRENT FUNDING
Project Title: Fluconazole plus flucytosine vs fluconazole alone for cryptococcal antigen-positive patients identified through screening: A randomised, controlled, non-inferiority trial
Role: co-Chief Investigator
Source of Funds: MRC Joint Global Health Trials (£4.7m) (April 2021 - March 2025)
Collaborators: NIMR, Tanzania; LSTM/LSHTM, UK; WITS/UCT, SA.
Description of Study: A pragmatic phase III RCT designed to determine whether combined oral therapy of fluconazole plus flucytosine improves outcomes, compared to fluconazole alone, for cryptococcal antigen (CrAg)-positive HIV-seropositive patients identified during CrAg screening in South Africa and Tanzania.
Project Title: Pathophysiology and clinical outcomes of subclinical cryptococcal meningitis (CM) (subEFFECT - Subclinical Cryptococcal Meningitis in patients excluded from participation in the EFFECT Study)
Role: Springboard Fellow
Source of Funds: Academy of Medical Sciences (£99,7200) (April 2022 – March 2024)
Description of Study: A prospective cohort study aiming to investigate the implications of subclinical CM on health and clinical outcomes over 6 months in 4 sites in SA and 3 in Tanzania.
Project Title: Improved flucytosine formulation for the treatment of meningitis in advanced HIV disease
Role: co-Investigator (DNDi is the lead organisation) leading the implementation of the Phase II study with colleagues in Malawi and Tanzania
Source of Funds: European and Developing Countries Clinical Trials Partnership (EDCTP) (€3.7 million) (2020-2024).
Collaborators: DNDi, UNC Project (Malawi), NIMR (Tanzania), FARMOVS (SA), Luxemburg Institute of Health.
Description of Study: A package of work, including Phase I and Phase II trials in SA, Malawi and Tanzania, aiming to develop a slow release formulation of flucytosine for treatment of Cryptococcal meningitis.
Project Title: Global Health Group on HIV-associated Fungal Infections (IMPRINT).
Role: co-Investigator, WP2 co-lead: Screening, EFFECT sub-studies, Study epidemiologist
Source of Funds: NIHR (£3 million) (2022 – 2026)
Collaborators: WITS/UCT (SA); MLW, Malawi; MSF, DNDi, LSTM/LSHTM, UK; Oxford CRU, Vietnam; Botswana-Harvard partnership, Botswana
Description of Study: This proposal brings together a team of leading researchers, clinical leaders, and NGO partners (MSF and DNDi), as well as civil society and patient representatives, to improve the diagnosis and treatment of these HIV-associated fungal infections.
Project Title: Implementing short-course treatment regimens for HIV-associated CM in sub-saharan Africa (SHARE-CM).
Role: co-Investigator
Source of Funds: CDC ($250,000 year 1 - up to $1m over 5 years in total) (2022 – 2027).
Collaborators: LSHTM, UK; BHP, Botswana; MLW, Malawi; IDI, Uganda; University of Zimbabwe.
Description of Study: This work aims to implement Implementing short-course treatment regimens for HIV-associated CM across 4 countries in sub-saharan Africa as shown to be effective through our recent clinical trial work.